Singleron Raises $30 Million for Gexscope® Single-Cell Analysis Technology

Singleron Biotechnologies, a Nanjing-Suzhou start-up developing its Gexscope® high-throughput single-cell multiplex analysis technology, completed a $30 million Series A round led by Lilly Asia Ventures. Founded in 2018, Singleron applies its single cell analysis technologies to clinical diagnosis, drug development and health management. Singleron will use the proceeds to develop its single-cell platform products and their clinical applications, to accelerate commercialization of its technologies and to build an international presence. More details.... Share this with colleagues: // //
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.